According to TipRanks.com, Sergott is ranked #3496 out of 5723 analysts.
Currently, the analyst consensus on Centogene NV is a Moderate Buy with an average price target of $17.50, representing a 35.1% upside. In a report released today, BTIG also initiated coverage with a Buy rating on the stock with a $18.00 price target.
The company has a one-year high of $15.59 and a one-year low of $11.81. Currently, Centogene NV has an average volume of 102.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Centogene NV is a commercial-stage company. It focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. It operates through the following two segments: Pharmaceutical and Diagnostics.